Bifogade filer
PM-Empli03 ENG-Emplicure-2022-12-22.pdf
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Emplicure and OnDosis will jointly evaluate development targets for oral delivery of active ingredients, based on their respective core competencies in formulation and dosing.
The collaboration between Emplicure, a company that combines proprietary bioceramic technology with tried and tested substances to develop tamper resistant formulations, and OnDosis, a Swedish life science company developing a new tamper resistent and tamper evident drug/device technology platform, will focus on enabling development of innovative treatments for chronic pain.
OnDosis has developed a handheld device that integrates medicine with intelligent dosing and digital capabilities. Emplicure has formulated a new product for pain relief, where the opioid buprenorphine is incorporated into the cavities of its proprietary bioceramics for controlled release.
"We are excited to have a partner to enhance our treatment of chronic pain," says Håkan Engqvist, CEO of Emplicure. "OnDosis shares our vision of putting patients in control by ensuring that they safely receive exactly the amount of medicine they need to live better lives."
"We are thrilled about the opportunity opened up by the collaboration with Emplicure," says Martin Olovsson, CEO of OnDosis. "The combination of OnDosis' and Emplicure's technologies forms a very strong logic and this partnership supports our mission to revolutionize how patients take their medicines."
Pain is a major health issue globally and, in the US, as many as 20% of the population are estimated to suffer from chronic pain and to need long-term pain relief. Widespread moderate to severe pain is a problem that is associated with significant costs for society and individual patients.
With their combined technologies, the companies see significant opportunities to pursue development of therapies that will address considerable unmet needs in the area of pain.
This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The informationen was submitted for publication, through the agency of the contact persons above, on January 20, 2023 at 12:18 CET.
For additional information, please contact
Håkan Engqvist
CEO, Emplicure
Phone: +46 702 569 500
Email: hakan.engqvist@emplicure.com
Martin Olovsson
CEO, OnDosis
Phone: +46 76 772 85 01
Email: m.olovsson@ondosis.com
Certified Adviser
Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.
The following documents can be retrieved from beQuoted
PM-Empli03 ENG-Emplicure-2022-12-22.pdf
Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com
OnDosis is a Swedish life-science company that is revolutionizing how patients take medicines. OnDosis' proprietary technology delivers the perfect dosage - individualized, intuitive, and intelligent - in a form that is easier to consume. The platform centers around a connected handheld device that enables integration of digital technologies and delivers customized and easily adjusted doses of oral medicines. Read more at www.ondosis.com